Clinical Trials Logo
  1. Home
  2. Renal Cell Cancer
  3. NCT00509704
  4. Details
NCT00509704 Clinical Trial

Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma

Renal Cell Cancer Clinical Trial

Official title:
Pilot Study on the Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00509704
Other study ID # CMO 2006/232
Secondary ID
Status Completed
Phase N/A
First received July 30, 2007
Last updated November 8, 2010
Start date October 2008
Est. completion date May 2010

Study information
Verified date October 2010
Source Radboud University
Contact n/a
Is FDA regulated No
Health authority Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study type Observational

Clinical Trial Summary

The purpose of the study is to assess the effect of Sunitinib on tumor vascularization and necrosis in patients with metastatic renal cell cancer.

Description:

Sutent is an angiogenesis inhibitor used in the treatment of renal cell cancer. Very often tumor necrosis is seen after the start of the treatment. It is unknown after how many days this effect starts. In patients with renal cell cancer with metastases, who will be treated with Sutent, 3 MRIs will be made. Kep, R2*, b-coefficient (perfusion, hypoxia, blood volume and necrosis) will be measured.

Recruitment information / eligibility
Status Completed
Enrollment 10
Est. completion date May 2010
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- patients with metastatic renal cell cancer for whom treatment with Sunitinib is planned

- histologically verified stage IV renal cell carcinoma of clear cell type

- measurable primary tumor or metastases (minimal diameter 2 cm) at other sites than the lungs

- Karnofsky score > 70%

- age > 18 year.

- written informed consent

Exclusion Criteria:

- contra-indications for MRI

- contra-indications for treatment with Sunitinib

- previous systemic treatment within the last 30 days

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
Netherlands UMC St Radboud Nijmegen

Sponsors (2)
Lead Sponsor Collaborator
Radboud University Novo Nordisk A/S

Country where clinical trial is conducted

Netherlands, 

See also
  Status Clinical Trial Phase
Completed NCT01392729 - An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA) N/A
Completed NCT00520403 - A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer. Phase 2
Completed NCT00694096 - Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response Phase 1
Completed NCT00216801 - Relationship of Ochratoxin A to Upper Urologic Cancers N/A
Completed NCT00172003 - Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Phase 4
Completed NCT02493751 - A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100) Phase 1
Recruiting NCT01967407 - IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy. Phase 1/Phase 2
Terminated NCT05061537 - Study of PF-07263689 in Participants With Selected Advanced Solid Tumors Phase 1
Completed NCT04535921 - Fear of Cancer Recurrence in Genitourinary Cancer
Recruiting NCT04620603 - Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer Phase 1/Phase 2
Completed NCT01829841 - A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer Phase 2
Completed NCT01122615 - Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC) Phase 1
Completed NCT00979329 - Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST N/A
Active, not recruiting NCT02429440 - Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides Phase 1/Phase 2
Active, not recruiting NCT02684006 - A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) Phase 3
Completed NCT02375776 - Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention N/A
Completed NCT01598597 - An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite) N/A
Completed NCT00465179 - Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer Phase 2
Completed NCT01158534 - Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery Phase 2
Terminated NCT00311467 - Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma Phase 3